Drug
penicillamine
penicillamine is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph early_phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Other(2)
Detailed Status
unknown2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
completed133%
unknown267%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_2
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
NCT06103617
unknownearly_phase_1
The Individual Therapy for Patients With Wilson's Disease
NCT03957720
completedphase_2
Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma
NCT00003751
Clinical Trials (3)
Showing 3 of 3 trials
NCT06103617Phase 2
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
NCT03957720Early Phase 1
The Individual Therapy for Patients With Wilson's Disease
NCT00003751Phase 2
Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3